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Breast cancer consists of at least fivemainmolecular
‘‘intrinsic’’ subtypes that are reflected in both pre-
invasive and invasive disease. Although previous
studies have suggested that many of the molecular
features of invasive breast cancer are established
early, it is unclear what mechanisms drive progres-
sion and whether the mechanisms of progression
are dependent or independent of subtype. We have
generated mRNA, miRNA, and DNA copy-number
profiles from a total of 59 in situ lesions and 85 inva-
sive tumors in order to comprehensively identify
those genes, signaling pathways, processes, and
cell types that are involved in breast cancer progres-
sion. Our work provides evidence that there are mo-
lecular features associated with disease progression
that are unique to the intrinsic subtypes. We addi-
tionally establish subtype-specific signatures that
are able to identify a small proportion of pre-invasive
tumors with expression profiles that resemble inva-
sive carcinoma, indicating a higher likelihood of
future disease progression.
INTRODUCTION
Approximately 20% of all breast cancer detected through
mammography are ductal carcinoma in situ (DCIS), a pre-inva-1166 Cell Reports 16, 1166–1179, July 26, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://sive form of the disease (Ernster et al., 2002). However, it has
been estimated that 20%–50% of DCIS tumors would progress
to invasive ductal carcinoma (IDC) if left untreated (Sanders et al.,
2005). Nonetheless, the natural history of DCIS and the exact
causes of disease progression are unknown, and we lack accu-
rate ways to identify at diagnosis those DCIS patients that may
be safely spared treatment (Cowell et al., 2013; Espina et al.,
2010; Falk et al., 2011; Kaur et al., 2013). A recent observational
study of more than 100,000 women found that the breast cancer
specific mortality rate following a DCIS diagnosis was about 3%,
emphasizing a need for markers that predict disease progres-
sion (Narod et al., 2015).
Both in situ and invasive breast tumors are comprised of het-
erogeneous phenotypes, with variation in clinicopathological
features such as histological grade, estrogen receptor alpha
(ER), progesterone receptor (PR), human epidermal growth fac-
tor receptor 2 (HER2/ERBB2), and epidermal growth factor
receptor (EGFR) status (Clark et al., 2011; Livasy et al., 2007).
Additionally, tumors of the different intrinsic subtypes are found
among both DCIS and IDC (Allred et al., 2008; Hannemann et al.,
2006; Muggerud et al., 2010; Vincent-Salomon et al., 2008), indi-
cating subtype-specific progression paths. DCIS lesions are
commonly found to have copy-number alterations that are
characteristic of the invasive disease, suggesting that genomic
instability is an early event in breast tumorigenesis (Berman
et al., 2005; Chin et al., 2004). Moreover, previous studies have
also suggested that clinical and intrinsic subtype, as opposed
to disease stage, are the dominant sources of variability among
tumor expression profiles (Hannemann et al., 2006; Muggerud
et al., 2010).).
creativecommons.org/licenses/by-nc-nd/4.0/).
Nonetheless, differences do exist in the proportions of lesions
within each disease stage that carry specific genomic features.
For example, a higher proportion of DCIS have amplification of
ERBB2 (Park et al., 2006; van de Vijver et al., 1988), while
FGFR1 (Jang et al., 2012) and MYC (Robanus-Maandag et al.,
2003) amplifications are more frequent in the invasive stage.
Among genomic studies, analyses in both bulk and microdis-
sected tissues have suggested that those genes differentially ex-
pressed between DCIS and IDC are functionally enriched for
changes in cell types and processes relating to the tumor micro-
environment (Lee et al., 2012; Ma et al., 2003, 2009; Vargas et al.,
2012). Similarly, others have provided evidence that epigenetic
changes contribute to breast cancer progression (Fazzari and
Greally, 2004; Fleischer et al., 2014; Widschwendter and Jones,
2002) and that the process may be mediated by myoepithelial
cells (Hu et al., 2008).
We previously identified a distinct subgroup of DCIS tumors
with characteristics of invasive disease and from this developed
a signature for the detection of similar tumors in independent
data (Muggerud et al., 2010). Consistent with other studies, we
found that high grade DCIS tumors are more likely than low
grade tumors to progress to the invasive disease (Fitzgibbons
et al., 1998; Hughes et al., 2009; Sanders et al., 2005) and sug-
gest that there are molecular properties present in some DCIS
that may be predictive of disease progression. Since tissues
tend to co-cluster by intrinsic subtype and not disease stage
(e.g., basal-like tumors are more highly correlated with other
basal-like tumors regardless of whether they are IDC or DCIS),
studies that investigate the molecular determinants of progres-
sion must incorporate subtype in a careful manner.
To address these issues, we have investigated the molecular
profiles of DCIS, lesions with a mixed diagnosis, small IDC tu-
mors using gene and microRNA (miRNA) expression analysis,
and SNP arrays for estimating DNA copy number. We identify
molecular features of progression that are unique to each sub-
type. Moreover, we demonstrate that features that differentiate
disease stage in an unstratified analysis are systematically
confounded by subtype. Our analysis further identifies a small
number of DCIS lesions with profiles suggesting they may be
more likely to progress to an invasive state. The features that
differentiate these DCIS from indolent DCIS may allow for the
identification of similar lesions at the time of diagnosis, which
may in turn have implications for treatment decisions.
RESULTS
DCIS and IDC Molecular Profiles Cluster According to
Intrinsic Subtype, but Signatures of Disease Stage Are
Observed within Subtype Clusters
To investigate the heterogeneity of mRNA profiles of DCIS and
IDC, we filtered for the most variable genes and performed class
discovery (see the Supplemental Information; Figure S1A). Sam-
ples divided into two main clusters primarily by ER status and
luminal characteristics. The intrinsic subtypes were differentially
enriched between the two clusters (Table S1, Fisher’s exact test,
and p value < 23 1010). This was also true for ER-positive sam-
ples (p value < 43 1011), HER2-positive samples (p value < 33
102), and samples of distinct grades (p value < 53 102). How-ever, neither cluster was enriched for the DCIS or IDC disease
stage, nor for lymph node-positive cases (p value > 0.05). Within
each of the two primary clusters, subclusters consisting of only
DCIS or IDC were observed. Together, this indicates that
although disease stage is not the primary source of variability
across breast gene expression data, systematic differences
are observed between DCIS and IDC within the main subgroups
of lesions.
Interestingly, analogous unsupervised analysis using the
miRNA data did not identify similar associations between pri-
mary clusters and clinicopathological features (see the Supple-
mental Information; Figure S1B). For the miRNA data, the two
primary clusters (i and ii) were enriched for significant differences
in disease stage (Table S1, p value < 23 102), but there were no
significant associations with intrinsic subtype, ER status, HER2
status, lymph node status, or grade (p value > 0.05). However,
when comparing primary cluster ii with subclusters iii and iv, sig-
nificant differential enrichments were found with respect to the
type of lesion (p value < 63 103) and intrinsic subtype (p value <
4 3 102). Correspondingly, we noted that cluster iii contains
only a single non-luminal lesion and that cluster iv contains
only a single IDC. No associations were found for HER2 status,
lymph node status, or grade.
Previously reported copy-number alteration events in breast
cancer were observed in multiple samples regardless of disease
stage. These include gains in chromosome 1q and 8q and losses
in chromosome 8p and 16q. As expected, high grade samples
had a higher frequency of copy-number alterations than low
grade samples. We confirmed this trend by calculating the
genomic grade index (GGI) (Chin et al., 2007) of the samples.
Grade III tumors were found to have significantly higher GGI
scores than the combined grade I and II scores (Figure S2A; p
value < 0.02). Similarly, samples classified as NormL had the
lowest GGI scores, and those classified as BasalL had the high-
est GGI scores (Figure S2B; p value < 9 3 104).
Tumors primarily clustered according to their ploidy (Fig-
ure S3, clusters i and ii), with all samples in cluster i having
apparent whole genome duplications. We did not observe sig-
nificant enrichments in these two primary clusters for stage of
lesion or other clinicopathological features (intrinsic subtype,
ER, HER2, lymph node, and grade; Table S1, p value > 0.05).
However, when comparing cluster i with subclusters iii and iv,
significant differences for enrichment were found between
intrinsic subtype (p value < 5 3 102) and grade (p value <
4 3 103). No other significant associations were found for clin-
icopathological features.
In summary, at each data level, sample clusters enriched for
intrinsic subtype were observed. This was a particularly domi-
nant signal at the gene expression level, where the subtypes
were originally defined. In order to determine whether combining
different data levels results in the identification of sample groups
systematically associated with different disease stages, we
calculated the IntClust subtypes (Curtis et al., 2012). Samples
belonging to each of the IntClust subtypes were observed,
with the exception of IC2 (Table S1). Overall, no significant differ-
ences were identified between the proportion of DCIS and IDC
assigned to each IntClust subtype (multidimensional Fisher’s
exact test and p value > 0.05). Similar findings were observedCell Reports 16, 1166–1179, July 26, 2016 1167
when investigating the proportion of DCIS and IDC assigned to
each transcriptionally derived intrinsic subtype (Table S1).
Intrinsic Subtypes Have Confounded Previous Attempts
to Differentiate Pre-invasive and Invasive Disease
Stages
Although breast lesions do not primarily divide according to the
disease stage, we were nonetheless able to identify 188 genes
differentially expressed between DCIS versus IDC (Figure 1A;
limma, adjusted p value < 0.05). This set was enriched for pro-
cesses such as collagen fibril organization, extracellular matrix
interactions, and focal adhesion, which are characteristic of cells
in the microenvironment (Table S1). This is in line with the types
of processes that have previously been identified as discrimi-
nating bulk expression profiles of DCIS from IDC. Furthermore,
our set of differentially expressed genes generally had a signifi-
cant degree of overlap with similarly derived signatures that
have previously been published (Hannemann et al., 2006; Knud-
sen et al., 2012; Lee et al., 2012; Ma et al., 2003, 2009; Porter
et al., 2003; Schuetz et al., 2006) (one-sided Fisher’s exact
test, Table S1).
Most publishedDCIS versus IDC signatures, and our list of 188
genes, contain at least one gene from the PAM50 gene set used
for intrinsic subtyping. Often the degree of overlap was statisti-
cally significant (one-sided Fisher’s exact test, Table S1).
The surprisingly high overlap between purported signatures of
DCIS versus IDC and classification markers of subtype moti-
vated a more detailed examination. Toward this end, we derived
a gene signature for each of the breast cancer intrinsic subtypes
(see the Supplemental Information). We compared the set of
genes that classified each subtype to our DCIS versus IDC
gene list and found that every subtype contributed a surprising
number of genes (Fisher’s exact test, LumA p value < 3 3
1012, LumB p value < 2 3 104, Her2E p value < 9 3 1015,
BasalL p value < 3 3 1014, and NormL p value < 5 3 1017).
One may expect that the genes that are differentially ex-
pressed between DCIS and IDC would be part of molecular pro-
cesses or cellularity that are ubiquitous across subtypes. In fact,
our signature demonstrated significantly different levels of acti-
vation between the subtypes (Figure 1B). Additionally, our
DCIS versus IDC gene list failed to separate DCIS from IDC
within the NormL subtype (Figure 1C). Together, this suggests
that frequently cited genes and signatures related to progression
from a pre-invasive to an invasive state are systematically incor-
rect for certain breast cancer subtypes.
In contrast to the mRNA data, we did not identify any miRNA
as differentially expressed between DCIS and IDC (limma,
adjusted p value < 0.05). The Volinia (Volinia et al., 2012) signa-
ture of nine miRNAs that were found to be differentially ex-
pressed between eight DCIS and 80 IDC tumors did not separate
DCIS lesions from IDC in our study, although four of these
miRNAs (miR-126, miR-143, miR-218, and miR-221) were differ-
entially expressed by raw p value (see Supplemental Informa-
tion; Figure S4).
We did not identify any genomic loci for which there were
consistent differential copy-number changes between DCIS
and IDC. Overall, relative copy-number gains of ERBB2 were
proportionately similar in all disease stages (3/39 DCIS, 4/641168 Cell Reports 16, 1166–1179, July 26, 2016IDC, and 2/16 mixed type; Fisher’s exact test and p value >
0.05). However, there was a trend toward a relative gain in
FGFR1 copy-number in invasive tumors (6/39 DCIS, 20/64
IDC, and 2/16 mixed type; p value < 2 3 102). Similarly, there
was a relative gain in MYC copy number in invasive tumors
(9/39 DCIS, 30/64 IDC, and 5/16 mixed type; p value < 5 3
102), consistent with previous studies (Jang et al., 2012; Roba-
nus-Maandag et al., 2003). Interestingly, MYC copy-number
gains were more significantly associated with the PAM50 sub-
type than with disease stage (p value < 8 3 104).
We additionally collected sequencing data on TP53 and
PIK3CA, the two genesmost frequentlymutated in breast cancer
(Cancer Genome Atlas Network, 2012). Here, we sought to
determine whether these mutation rates differ between DCIS
and IDC, possibly as a result of the accumulation of de novo
mutations during disease progression. However, the mutation
rates were similar between DCIS and IDC for both genes, sup-
porting the notion that such mutations are acquired at an earlier
disease stage than DCIS (Table S1, Fisher’s exact test, and
p value > 0.05).
Subtype-Specific Measures of Progression Are Disjoint
Given the confounding we observed between histopathological
variables, intrinsic subtype, and disease stage, we generated a
linear model that incorporates the variables of ER status, HER2
status, tumor grade, and intrinsic subtype into the identification
of differentially expressed genes between DCIS versus IDC
(see the Supplemental Information). The model identified six
significantly differentially expressed genes: AS3MT, FAM74A4,
GPR155, PQLC2, SLC16A12, and ZNF865 (limma, adjusted
p value < 0.05). Interestingly, none of these genes were identified
in our previous univariate analysis (Table S1), further indicating
that the identification of genes that differentiate disease stage
is confounded by clinicopathological variables and subtype.
Although this multivariate modeling approach was able to
identify a small number of genes differentially expressed inde-
pendently of intrinsic subtype, variables such as ER status are
known to affect the transcriptional levels of thousands of genes,
with complicated interactions with other variables such as the
proliferative index of the tumor. As such, a simple linear model
may not suffice to ablate the effects of these ubiquitous con-
founders. Patient stratification by subtype provides an alterna-
tive approach that potentially handles ubiquitous effects more
appropriately. Under the hypothesis that DCIS lesions of any
given subtype are most likely to progress to invasive tumors of
the same subtype, we repeated our supervised class distinction
approach by contrasting only DCIS versus IDC of the same sub-
type. Because there are a much smaller number of samples in
each of these analyses in comparison to the unstratified analysis,
we anticipated having less power, which in turn affects the num-
ber of features meeting a given significance threshold (Stretch
et al., 2013). In order to compensate for these differences, we
used a false discovery rate (FDR) cutoff of less than 0.05 for
the within subtype analyses. The resultant gene lists are highly
distinct across the subtypes, sharing no genes in common be-
tween all of them (Figures 2A and 2B; Table S1). Additionally,
these lists differed in their ability to split DCIS from IDC. This
was especially apparent among the LumA, LumB, and Her2E
AC
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subtypes, slightly less consistent with the BasalL subtype, and
entirely untrue for the NormL subtype, where DCIS and IDC sam-
ples were always intermixed. The differences in the size of these
gene lists (775 LumA, 90 LumB, 227 Her2E, 120 BasalL,
and 0 NormL) did not appear to be directly related to the number
of samples in the associated comparisons (12 versus 19 LumA,
seven versus 14 LumB, 11 versus six Her2E, five versus 11
BasalL, and ten versus six NormL). They also did not appear to
be related to the degree of heterogeneity within each subtype,
as witnessed by similarities in the interquartile range distribu-
tions across all genes on the array, within each subtype
(Figure S5A).
To further investigate the relationship between disease stage
classification signatures and their within-subtype performance,
we additionally obtained signatures relating to disease progres-
sion in breast cancer from both literature and database
sources. The majority of these signatures were generated by
directly contrasting gene expression of DCIS versus IDC. Across
the unstratified and subtype-stratified cohorts, we used naive
Bayes classifiers with a leave-one-out cross-validation strategy
to determine how well each signature is able to predict disease
stage (Figure 3; Table S1, see the Supplemental Information).
A small number of samples were consistently incorrectly pre-
dicted for all signatures; in particular, NormL samples tended
to always be classified as DCIS. In general, the signatures
with the best performance differed in each subtype, although
our 188 gene signature that differentiates all DCIS from IDC
within our unstratified cohort, labeled ‘‘Lesurf 2016 (unstrati-
fied)’’, was among the best performing signatures in all sub-
types. Moreover, the proportion of signatures that significantly
predicted disease stage (Fisher’s exact test, p value < 0.05) var-
ied by cohort stratification, with 97% of signatures significant in
the unstratified cohort and only 8% significant within the NormL
subtype.
Biological Processes that Distinguish DCIS from IDCAre
Related to the Microenvironment
Next, we performed hierarchical clustering across the unstrati-
fied cohort using the union of differentially expressed genes
from our unstratified and subtype-specific lists. We observed
four main clusters of genes, with various degrees of overlap
between subtypes (denoted i–iv; Figure 4). Gene Ontology
(GO) enrichment analysis revealed that each cluster is defined
by biologically distinct processes (Table S1). Cluster i was
enriched for metabolic processes, ii for pathways relating to
cell development and structure, iii for various forms of
immune response, and iv for genes related to the extracellular
matrix.
Several tools were used to additionally investigate the path-
ways and processes that differentiate DCIS from IDC within
each intrinsic subtype (Table S1, see the Supplemental Informa-Figure 1. Classification Signature of Breast Disease Stage
(A) Genes differentially expressed between DCIS and IDC. The upregulated and do
the heatmap, respectively. The tumors are ordered according to an increasing ran
(B) Boxplots representing tumor ranks stratified by each intrinsic subtype with re
(C) Boxplots representing tumor ranks stratified by disease stage type. The ranks
subtype in the other boxes.
1170 Cell Reports 16, 1166–1179, July 26, 2016tion). Overall, we found that the LumA, LumB, and Her2E sub-
types shared many common pathways, especially those related
to collagen fibril organization, cell adhesion, and ECM-cell re-
ceptor interactions. They also tended to share pathways that
were differential between DCIS and IDC in the unstratified anal-
ysis. Nevertheless, there were also pathways specific to each of
these subtypes, including cell differentiation and inflammatory
immune responses for LumA, cell migration signatures for
LumB, and enrichment for cell-cycle signatures in Her2E. The
BasalL subtype was primarily enriched for properties related to
the immune response, particularly with T cells, but there was
also some evidence of B cell, immunoglobulin A, and natural
killer cell presence. Finally, within the NormL subtype, no genes
or gene sets were found to be differentially expressed between
DCIS and IDC.
To further determine the role of the microenvironment in differ-
entiating pre-invasive from invasive lesions, we investigated
whether the genes differentially expressed between DCIS versus
IDC also tend to be differentially expressed between epithelial
and stromal tissue. Using two previously published data sets
containing microdissected cell compartments from pre-invasive
and invasive lesions (Lee et al., 2012; Ma et al., 2009), we found
that in almost all cases there was significant overlap between our
DCIS versus IDC gene lists and gene lists that differentiate the
epithelial tissue from the stromal compartment of both DCIS
and IDC (limma, FDR < 0.05 followed by a Fisher’s exact test).
The LumA subtype had the most significant overlaps (p value <
23 1019 and 23 1082 in the Lee andMa lists, respectively) fol-
lowed by Her2E (p values < 0.03 and < 6 3 1005). The BasalL
and LumB subtypes were significantly only in the Ma list
(p values < 0.02). Additionally, the list of genes differentially ex-
pressed between DCIS and IDC in the unstratified analysis was
also significantly associated with the tumor microenvironment
(p values < 5 3 104 and 1 3 1025 for Lee and Ma lists,
respectively).
Next, we asked whether there were miRNAs that were differ-
entially expressed between DCIS and IDC per intrinsic subtype
(Figure 2C). Only two miRNAs were identified for the LumA sub-
type (miR-10a* and miR-323-3p, both higher in IDC) and two for
the Her2E subtype (miR-298 and miR-4300, both higher in IDC).
Six miRNAs were higher in BasalL DCIS compared to IDC (miR-
34c-5p, miR-95, miR-133b, miR-192, miR-218, and miR-363),
one was lower (miR-K12-5*), and one miRNA (miR-136) was
higher expressed in IDC compared to DCIS for the NormL
subtype.
As with the earlier unstratified analysis, we were unable to
identify systematic differences in copy-number or mutation rates
of TP53 and PIK3CA between the DCIS and IDC of each intrinsic
subtype (Table S1). This is consistent with previous data demon-
strating that changes at the DNA level occur early in breast
tumorigenesis (Newburger et al., 2013).wnregulated genes in IDC are denoted by red and green bars on the left side of
k-sum, and rank-sum scores are plotted as black bars on top of the heatmap.
spect to the signature shown in (A).
for all patients are shown in the upper left box and for each separate intrinsic
AB C
(legend on next page)
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Predicting DCIS Patients that Are Most Likely to
Progress
Although it is believed that not all DCIS lesions will progress to
an invasive stage even in the absence of treatment, we still
lack a means to distinguish between such indolent and
aggressive DCIS. To this end, we have sought to identify DCIS
lesions with invasive-like properties, under the hypothesis
that these properties may be used as a classifier for likely
progressors.
Under a leave-one-out cross-validation strategy within each
subtype, we performed class distinction between IDC and
DCIS after removing the single DCIS sample (limma, FDR <
0.05). Then using these genes as a basis set, we applied hierar-
chical clustering. The samples that clustered closest were
compared to the true lesion type of the left-out patient. This pro-
cess identified two LumA, one LumB, oneHer2E, and one BasalL
DCIS that clustered among the IDC; no NormL DCIS were iden-
tified, due to a lack of differentially expressed genes in each anal-
ysis (Figure 5A). These numbers are roughly concordant with
estimates of indolent/aggressive DCIS from the literature (Page
et al., 1982, 1995; Sanders et al., 2005). Although this investiga-
tion was not designed to study prognosis due to small sample
size and selection of cases, we noted that one of these two
‘‘invasive-like’’ LumA DCIS lesions is known to have locally
recurred, and similarly the only patient with an ‘‘invasive-like’’
Her2E DCIS has developed a distal invasive recurrence, sug-
gesting the approach may in fact have efficacy to identify
in situ tumors likely to progress.
For each of the intrinsic subtypes, we identified the genes that
were significantly differentially expressed between those ‘‘inva-
sive-like’’ DCIS and the remaining indolent samples and further
filtered these lists by how consistently the genes were up- or
downregulated in both IDC and ‘‘invasive-like’’ DCIS (Table S1,
see the Supplemental Information). In total, 1,667 genes were
identified across these four lists (1,283 LumA, 79 LumB, 261
Her2E, and 131 BasalL). We term these gene sets ‘‘invasive sig-
natures’’. Although there was a small degree of overlap between
the invasive signatures across the subtypes, there were not any
genes common to all subtypes (Figure S5B). Interestingly, the
invasive signatures were often enriched in pathways/processes
that were distinct from the pathways/processes identified as dif-
ferential between DCIS and IDC. The LumA invasive signature
was primarily enriched for immune-related processes, as well
as cell metabolism and cell cycle. The LumB invasive signature
was also enriched for immune-related processes, including in-
flammatory responses, as well as cell-cell signaling. The Her2E
invasive signature was enriched for cell adhesion, ECM-receptor
interaction, cell motility, and cell morphogenesis. Finally, the
BasalL invasive signature was primarily enriched for immune-
related processes, predominantly those involving cytokine and
inflammatory responses.Figure 2. Subtype-Stratified Classification Markers of Disease Stage
(A) Genes that are differentially expressed between DCIS and IDC in either an un
subtype. The patients are ordered according to an increasing rank-sum by the
heatmaps are colored according to whether they are significant in each analysis
(B) Venn diagram representing number of genes differentially expressed betwee
(C) Venn diagram representing number of miRNA differentially expressed betwee
1172 Cell Reports 16, 1166–1179, July 26, 2016The invasive signatures were applied to previously published
gene expression data sets in order to determine whether we
could identify invasive-like DCIS. Notably, however, these data
sets were smaller in size than our own, making it difficult to
discern invasive patterns. Nonetheless, we were able to identify
a small number of LumB and BasalL DCIS samples that express
their respective invasiveness signature at a high level (Figure 5B,
yellow arrows). Again, the number of invasive-like DCIS tumors
that we identify is consistent with previous reports indicating
that only a small proportion of pre-invasive tumors have the ca-
pacity to become invasive over time.
DISCUSSION
Today, approximately one in five breast malignancies detected
by mammography are diagnosed as DCIS. DCIS continues to
pose a difficult clinical challenge as we still cannot distinguish
cases that would remain indolent and therefore do not require
intensive treatment from cases that are likely to progress to
IDC. Therefore almost all DCIS cases are treated with excision,
often followed by radiation and hormonal therapy (Allred et al.,
2012; Punglia et al., 2013; Wa¨rnberg et al., 2014). However, at
least 50% of DCIS would never progress to an invasive state if
left untreated, implying many women needlessly undergo treat-
ment with potentially harmful side-effects (Vatovec et al.,
2014). An increased understanding of the tumor properties that
drive disease progression, and an investigation into whether
some of these properties are already present within (a minority
of) pre-invasive lesions, is needed.
Our finding that gene expression profiles cluster patients pri-
marily by breast cancer subtype and then according to disease
stage is concordant with previous reports. Moreover, we demon-
strate that signatures derived in unstratified analysis to differen-
tiate DCIS from IDC are indeed confounded by intrinsic subtype;
the observed differences in expression are more associated with
subtype than with stage of disease. We note that previous
studies may have been unable to observe these confounding ef-
fects because of their smaller sample size.
In order to overcome the association between intrinsic sub-
type and classification markers of invasiveness, we stratified
tumors according to their intrinsic subtype and identified tumor
properties that differentiate DCIS from IDC. Although our data
set is relatively large, we note that these stratified analyses
reduced the power to identify differentially expressed genes,
particularly within the NormL subtype where no genes were
identified. Nonetheless, these analyses highlighted substantial
differences between the subtypes, in turn leading to the hy-
pothesis that each subtype undergoes a distinct evolutionary
course of disease progression from pre-invasive to invasive
stage. However, among the different subtypes, it is interesting
that most of these properties do not represent molecularstratified or PAM50-stratified analysis are displayed as heatmaps within each
ir intrinsic subtype and type of lesion. The gene tick marks to the left of the
.
n DCIS and IDC within each intrinsic subtype.
n DCIS and IDC within each intrinsic subtype.
A B
Figure 3. Patient-Signature Heatmap of Signatures of Progression in Cancer
(A) Subtype-specific performance of signatures is represented. The colors are proportional to the rank of the classifier within the specific patient cohort, with red
representing the highest-performing signatures. The ticks represent the level of significance of the classifier by Fisher’s exact test. The percentage of significant
signatures at p value < 0.05 is shown in parentheses.
(B) Yellow and purple shaded columns correspond to DCIS and IDC, respectively. The signatures (rows) are ordered by their ability to predict tissue type in the
unstratified cohort. The dark and light shades correspond to correct and incorrect predictions, respectively. The patients (columns) are ordered by the degree of
agreement of predictions across all signatures. A description of the signatures used is available in Table S1.
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Figure 4. Subtype-Stratified Classification Markers of Tumor Stage Hierarchically Clustered across All Samples
Heatmap of genes that are differentially expressed between DCIS and IDC in either an unstratified or subtype-stratified analysis. The patients are sorted by their
intrinsic subtype and type of lesion. The gene tick marks to the left of the heatmap are colored according to whether they are significant in each analysis.events that occur within the epithelial tumor cells, but rather
reflect changes that include involvement of the microenviron-
ment. This supports the increasing evidence of the role that
non-epithelial events play in tumor progression and disease
outcome.1174 Cell Reports 16, 1166–1179, July 26, 2016Although we identified miRNAs as differentially expressed
between DCIS and IDC within each subtype, none were shared
between the subtypes. Some of these have been previously
implicated in cancer. For example, the miR-10 family has been
demonstrated to be involved in Hox gene transcription factor
AB
(legend on next page)
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signaling, with high expression associated with various cancer
types, including breast (Lund, 2010; Ma et al., 2007). miR-298
may be involved in chemoresistance in breast cancer (Bao
et al., 2012). miR-34c-5p is induced by a hypoxia (Xu et al.,
2012), and miR-192 is involved in p53-mediated MDM2 expres-
sion (Pichiorri et al., 2010). miR-133b and miR-136 are involved
in apoptosis (Patron et al., 2012; Yang et al., 2012). Additionally,
miR-133b regulates the oncogeneMET (Hu et al., 2010) and pro-
motes cell proliferation through ERK and AKT1 (Qin et al., 2012).
Interestingly, miR-K12-5* is derived from Kaposi’s sarcoma-
associated herpesvirus, which is sometimes present in the lym-
phocytes of individuals. Its high expression in invasive BasalL
breast cancer is consistent with the high expression of lympho-
cytic markers in these tumors. We note, however, that as fewer
DCIS and IDC samples were profiled for miRNA expression,
this analysis had limited power to detect differentially expressed
miRNA.
At the DNA level, tumors displayed heterogeneous profiles,
even after stratification by intrinsic subtype. This is in line with
previous studies of the DNA profiles of DCIS (Buerger et al.,
1999a, 1999b; O’Connell et al., 1998), which have suggested
that they are only partially correlated with gene expression pro-
files derived from the same tumors. Similar mutation patterns
and frequencies in TP53 and PIK3CAwere found in DCIS lesions
compared with invasive tumors, which is consistent with what
has previously been reported (Miron et al., 2010). Mutations in
these two genes, which are the most frequently mutated in
breast cancer, are strongly correlated with breast cancer sub-
types and are therefore less likely to reflect within subtype differ-
ences between DCIS and IDC. Future studies based on
massively parallel sequencing may identify clonal differences
between DCIS and IDC and aid in the identification of somatic
mutations and chromosomal aberrations that differentiate be-
tween disease stages (Kaur et al., 2013). Although our study
was conducted on a relatively large sample set of DCIS, having
a higher number of pre-invasive lesions would improve the
power to extend our findings in the subtype-stratified analyses.
A critical question that remains is whether it is possible to pre-
dict which DCIS lesions are most likely to progress if left un-
treated, in order to spare patients from unnecessary treatment.
Although previous studies and tests have sought to identify
markers of disease recurrence in patients with DCIS (Rakovitch
et al., 2015; Solin et al., 2013), it is important to differentiate be-
tween an in situ recurrence and an invasive recurrence. To this
end, we used a series of leave-one-out analyses to identify a mi-
nority of DCIS tumors that have gene expression profiles resem-
bling invasive tumors. Although all DCIS caseswere assessed by
pathologists to ensure that only pure DCIS were included in this
group, it is possible that, due to spatial heterogeneity within the
lesions, our analysis identifies tissues with micro-invasive com-Figure 5. Subtype-Specific Signatures of Tumor Progression
(A) Heatmaps showing differentially expressed genes between DCIS and IDC-lik
invasive-like and cluster here among IDC. The genes that follow similar patterns
right of heatmaps and form the basis of our progression signatures.
(B) Progression signatures were applied to four other data sets (Hannemann et
patients are each ordered from left to right according to a rank-sum algorithm (see
the far right, indicating that they possess invasive-like components within their g
1176 Cell Reports 16, 1166–1179, July 26, 2016ponents that were not otherwise reported. While studies using
microdissection would resolve this concern, they may lack the
sensitivity to identify such potentially important cases. We addi-
tionally used the identification of these lesions to further develop
subtype-specific signatures that predict invasiveness. Interest-
ingly, all of these signatures again highlight a role for the tumor
microenvironment in driving disease invasion. In particular,
gene enrichment for immune response pathways was observed
in multiple subtypes. Together, these results suggest that such
properties could be used to differentiate between DCIS patients
who require further treatment or who could be spared disease
therapy.
EXPERIMENTAL PROCEDURES
This study has been approved by the appropriate ethical committees (Norwe-
gian Regional Committee for Medical Research Ethics, 1.2006.1607, and the
Ethics Committee at Uppsala University, Sweden, Dnr 2005:118).
Tissue Processing
Tumor tissues were obtained from the Fresh Tissue Biobank, Department of
Pathology, Uppsala University Hospital, Sweden; the Breast Cancer Tissue
Bank, St. Olav’s University Hospital, Trondheim, Norway; the Norwegian
Radium Hospital and Ulleva˚l University Hospital, Oslo University Hospital,
Oslo, Norway; and Akershus University Hospital, Lørenskog, Norway. Expert
pathologists reviewed all cases to ensure that no invasive components were
found in the pure DCIS. For grade, DCIS lesions were classified according to
European Organization for Research and Treatment of Cancer (EORTC)
scores, and IDC and the invasive part of tumors with a mixed diagnosis
were classified by using the Elston-Ellis scores. Individual tissue clinical char-
acteristics are found in Table S1 and a summary of these characteristics is
available in Table 1.
Microarray Analysis
mRNA and miRNA expression analysis was performed using Agilent SurePrint
G3 Human GE 8x60K Microarrays and Human miRNA Microarray Release
16.0, 8x60K, respectively. Copy-number analysis was performed using Affy-
metrix Genome-Wide Human SNP array 6.0. Details on data analysis can be
found in the Supplemental Information.
Statistical Methods Rank-Sum Algorithm for Tumor Ordering
We use the rank-sum linear ordering algorithm to sort tumors according to
increasing activation levels of signatures. For a given signature with k genes,
each gene univariately ranks all patients according to the level of expression
of that gene and that patient. For many signatures in the literature including
the majority of signatures used here, we have prior knowledge regarding
whether each of the genes is over- or under-expressed in the control and
experimental groups. For example, if we had a signature of ER activation,
we might expect that ESR1 would be overexpressed in the ER-positive sub-
group of patients. Symmetrically, we might expect that markers of the BasalL
subtype might be under-expressed. For a gene that is expected to be overex-
pressed in our experiment, each patient is ranked from 1 to m where 1 is the
least amount of expression witnessed for that gene, and m is the highest
observed expression of that gene. Similarly, for genes expected to be
under-expressed, the patients are ranked from m to 1. The sum of ranks fore lesions within each intrinsic subtype. A total of five DCIS were classified as
within true IDC and invasive-like DCIS are shown by red and green bars to the
al., 2006; Lee et al., 2012; Muggerud et al., 2010; Schuetz et al., 2006). Here,
Supplemental Information). A small number of DCIS in these data sets order to
enomic profiles.
Table 1. Summary of Patient and Tumor Characteristics
DCIS IDC Mixed Total
Number of samples 59 85 16 160
Number of expression arrays 46 56 0 102
Number of microRNA arrays 26 14 0 40
Number of SNP arrays 42 67 16 125
Age in years, median (range) 56.5 (30–82) 57 (36–90) 57 (27–89) 57 (27–90)
Size in millimeters, median (range) 25 (7–60) 11 (1–30) 15 (8–40) 13 (1–60)
Elston grade, I/II/III N/A 25/32/28 6/7/3 31/39/31
EORTC grade, I/II/III 3/14/35 N/A 0/6/7 3/20/42
Combined grade, I/II/III 3/15/35 26/32/27 6/7/3 35/54/65
ER+/ER (%) 26/11 (70) 64/21 (75) 9/7 (56) 99/39 (72)
PR+/PR (%) 23/14 (62) 59/26 (69) 8/8 (50) 90/48 (65)
HER2+/HER2 (%) 12/22 (35) 23/53 (30) 13/2 (87) 48/77 (38)
Lymph node+/lymph node (%) 0/46 (0) 13/43 (23) 0/0 (N/A) 13/88 (13)
LumA (%) 17 (29) 28 (33) 4 (25) 49 (31)
LumB (%) 10 (17) 22 (26) 1 (6) 33 (21)
Her2E (%) 12 (20) 11 (13) 5 (31) 28 (18)
BasalL (%) 8 (14) 14 (17) 3 (19) 25 (16)
NormL (%) 12 (20) 9 (11) 3 (19) 24 (15)
Combined grade uses Elston grade in invasive and mixed tissues and EORTC grade in DCIS tissues; variables have some missing data; and percent-
ages are calculated with the missing data omitted.each patient are calculated, and the patients are ordered left to right (from least
to greatest sum), representing least to greatest activation of the signature
accordingly.
Methodology to compute statistical associations between patient orderings
and the state of clinicopathological variables followed our previously
described approach. TheMann-Whitney-Wilcoxon test was used to determine
associations with type of lesion, whereas the Kruskal-Wallis test was used to
determine association with intrinsic subtype.
Identification of Invasive-like DCIS Tumors
Our method to identify DCIS tumors with invasive-like molecular components
to their profiles proceeded as follows. (1) Within each subtype, DCIS tumors
were sequentially removed under a leave-one-out approach, and differentially
expressed genes were identified between the remaining DCIS versus IDC
samples as previously described. All samples belonging to that subtype
(included the sample that had been removed) were then hierarchically clus-
tered. In some cases, the left-out DCIS clustered most closely with IDC.
(2) We collected a set of over 6,421 gene signatures from MSigDB (Subrama-
nian et al., 2005), GeneSigDB (Culhane et al., 2012), and the literature. For each
signature and within each subtype, samples were sorted by our rank-sum
algorithm for tumor ordering (described above). Within each subtype, DCIS tu-
mors were sequentially removed under a leave-one-out approach, and gene
signatures with significantly different sample ranks were identified between
the remaining DCIS versus IDC samples as previously described. All samples
belonging to that subtype (included the sample that had been removed) were
then hierarchically clustered over the sample ranks of filtered signatures.
Those DCIS that clustered among IDC in both (1) and (2) were designated as
having invasive-like properties.
After we identified a small number of invasive-like DCIS tumors belonging to
the LumA, LumB, Her2E, and BasalL subtypes, we re-classified these tumors
into the IDC group. For each of these four subtypes, the genes differentially ex-
pressed between DCIS and IDC were identified as previously described.
These genes were next hierarchically clustered and plotted into a heatmap.
Gene clusters that followed consistent patterns within IDC and invasive-like
DCIS were visually determined and formed the basis for each progression
signature.ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO:
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